Table 3 Associations between AcPGP and COPD exacerbations
From: The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS
No severe AECOPD (n = 155) | Severe AECOPD (n = 18) | P-value | |
|---|---|---|---|
Sputum AcPGP | 0.019 | ||
Q1 Q2 Q3 Q4 | 42 (28%) 41 (27%) 38 (25%) 31 (20%) | 2 (11%) 1 (6%) 7 (39%) 8 (44%) | |
Sputum AcPGP above median | 69 (45%) | 15 (83%) | 0.002 |
Plasma AcPGP | 0.96 | ||
Q1 Q2 Q3 Q4 | 37 (24%) 38 (25%) 41 (27%) 39 (25%) | 5 (28%) 4 (22%) 4 (22%) 5 (28%) | |
Plasma AcPGP above median | 73 (47%) | 11 (61%) | 0.27 |